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The present work was designed to study H. pylori infection in type 2 DM, its relation to some 
clinical; metabolic and radiological markers of atherosclerosis and vascular complications in type 
2 DM.  
Methods 
 The study included sixty type 2 diabetic patients and fifteen healthy controls matched with age 
and sex. Both patients and controls were subjected to full history taking, clinical examination, 
estimation of BMI, resting ECG. laboratory tests including HbA1C, FBG, Serum creatinine; Lipid 
profile; fibrinogen assay, ES5; C53; T1F ǂ; IL-6; IL-1B; H. pylori IgG. 24 hours and urine collection 
for urinary albumin excretion. Radiological investigations include aabdominal ultrasound. 
Ultrasound on the carotid arteries used in measuring the intima-medial thickness (IMT).  
Results 
 The present study found non significant increase in prevalence of H. pylori infection in type 2 
diabetic patients in relation to controls. H. pylori infection had no relation to sex, age of the 
patients, duration of diabetes, BMI, type of therapy or the degree of diabetic retinopathy. H. pylori 
infection did not affect levels of FBG, HbA1c and microalbuminuria and caused a significant 
increase in the level of triglycerides, T1Fǂ, IL-1B, CRP and fibrinogen, decrease in the level of 
HDL and non significant effect on WBCs count, the levels of  total cholesterol , LDL, ESR and IL-6 
in type 2 diabetic patients. H. pylori infection does not affect IMT of both Right and Left common 
carotid arteries. No significant increase of the prevalence of H. pylori infection among diabetic 
patients with diabetic vascular complications. 
Conclusion 
 There is no significant increase in prevalence of H. pylori infection among type 2 diabetic 
patients. H. pylori infection is not related to patient age, degree of glycaemic control, IMT or 
diabetic vascular complications among type 2 diabetic patients. However, H. pylori infection 
could affect atherosclerotic process through its effects on lipid profile (increase in TG and decrease 
HDL levels), increase levels of inflammatory cytokines (TNF-alpha and IL-1B) and acute phase 
reactants (CRP and Fibrinogen).  
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 Introduction 
he chronic hyperglycemia of diabetes is 
associated with long term damage, 
dysfunction and failure of various organs 
especially the eyes, kidneys, nerves, heart 
and blood vesselsP1P. At least 80% of the 
diabetic patients will die predominantly 
from the consequences of vascular 
complicationsP2P. Review of epidemiological 
studies indicates that classic risk factors for 
atherosclerosis account for majority but not 
the entirety of the etiology and pathogenesis 
of the clinical complications of 
atherosclerosis, including ischemic heart 
diseases. The inability of traditional risk 
factors to completely explain the incidence 
and trends in cardiovascular diseases has 
resulted in repeated calls for a search for 
new risk factors. Infections have been placed 
among these new putative risk factors P 3 P.  
Infection with Helicobacter pylori (H. Pylori; 
gram negative bacteria) has been 
epidemiologically linked to some 
extradigestive conditions, including 
ischemic heart disease, diabetes mellitus and 
othersP4P. Diabetic patients are at risk of 
cardiovascular and thrombo-occlusive 
cerebral diseases. There is a possible 
relationship between H. pylori infection and 
cardiovascular or cerebrovascular diseasesP5 P. 
The finding that infectious agents are 
responsible for chronic diseases of unknown 
cause is not new. Chronic H. pylori 
colonization may be associated with an 
increased risk for atherosclerosis. The 
underlying hypothesis is that H. pylori 
infection has atherogenic capacities by 
chronic low-grade activation of the 
haemostasis cascade P6P.  
The association between H. pylori and acute 
cerebrovascular disease seems to be due to a 
higher prevalence of more virulent H. pylori 
strains in patients with atherosclerotic 
stroke P7P.  
Chronic H. pylori infection was associated 
with a higher risk of stroke due to small 
artery occlusion and a lower risk of cardio 
embolic stroke. Chronic H. pylori infection 
still showed an over all association with 
ischemic stroke after adjustment of major 
cardiovascular risk factors. These suggest 
that chronic H. pylori infection may be a 
triggering factor that increases the risk of 
acute ischemic stroke P8P. The present work 
was designed to study H. pylori infection in 
type 2 DM, its relation to some; metabolic 
and radiological markers of atherosclerosis 
and vascular complications in type 2 DM.  
 
Materials and Methods 
 
Sixty patients of known diabetes type 2, age 
range of 30-60 years enrolled from 
outpatient’s clinic of endocrinology unit of 
Mansoura specialized medical hospital, 
Mansoura University. The studied cases 
were enrolled during summer months of 
2005. Patients with chronic liver diseases; 
cardiac diseases; renal impairment; acute 
medical insults and Patients with other 
endocrinal diseases were excluded from the 
study. Fifteen healthy adults of matched age 
and sex were taken as control group. This 
descriptive study was approved by the local 
ethical committee from the Scientific 
Research at Mansoura University hospital, 
Egypt. Informed consent was obtained from 
all subjects before the beginning of the 
study. 
Diabetes mellitus was diagnosed according 
to the Report of the expert committee on the 
diagnosis and classification of DM P9P.  
Both patients and controls were subjected to 
full history taking with stress upon cardiac 
risk factors, diabetic history and findings of 
vascular complications. Full clinical 
examination was done including cardiac 
risk factors; blood pressure, resting 
electrocardiogram, body mass index and 
(BMI) was calculated according to the 
following Formula: (Weight) in Kg/ 
(Height) P2P in meter.  
Macrovascular diabetic complications were 
diagnosed by presence of findings 
suggestive ischemic heart, peripheral 
vascular or cerebrovascular diseases. 
Retinopathy was diagnosed by simple direct 
ophthalmoscope and/or by 
ophthalmologist. Diagnosis of nephropathy 
was considered by the presence of persistent 
albuminuria of 20 to 200 mg/24 hours 
(microalbuminuria) in at least three 
occasions in absence of UTI.
T 
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Macroalbuminuria was diagnosed when 
persistent albuminuria equals or exceeds 300 
mg/24 hours10. Urinary albumin 
concentration was measured by 
Radioimmunoassay.  
Laboratory investigations including 
complete blood picture and HbA1C, 
fibrinogen assay, ESR; FBG, Liver function 
tests (SGOT, SGPT, serum albumin); Serum 
creatinine; Lipid profile; CRP; TNF ǂ; IL-6; 
IL-1B; and H pylori IgG. 24 hours Urine 
collection for detection of microalbuminuria.  
24-hour collections were used for 
determination of daily excretions of total 
albumin. Urinary albumin excretion was 
measured by Quantitative Turbidimetric 
Determination of Total Protein. Kits were 
supplied from Stanbio laboratories, USA. 
Morning blood samples were collected after 
a 12 hour fast; 10 ml venous samples were 
withdrawn and aliquot into tubes under 
aseptic conditions as follows: sodium 
fluoride plasma for determination of 
glucose, serum for determination of the lipid 
profile (total cholesterol, HDL-C, LDL-C 
and triglycerides). The EDTA samples were 
stored on ice (-80) between the time of 
sampling and centrifugation for 
determination of Serum Fibrinogen, CRP, 
IL-6, IL-1E & TNF-alpha levels. A high 
sensitivity enzyme linked immunosorbent 
assay (ELISA) was used. 
Blood picture was done using CEII DYNE 
1700 U.SA blood count analyser. Human 
Germany supplied prospective kits and 
reagents for assay of Liver functions tests, 
Erythrocyte sedimentation rate (ESR) was 
assessed manually at 1and 2hrs. HbA1C 
assay done using Quantitative Colorimetric  
Determination of Glycohema globin in 
whole blood supplied by Stanbio 
Laboratory, Texas, USA. The plasma glucose 
level was measured by an automated 
enzymatic method on the Hitachi 911 
analyzer using Roche Diagnostic’s regents 
(Indianapolis, IN). Serum levels of total 
cholesterol, triglyceride, and HDL 
cholesterol were measured by enzymatic 
methods using an autoanalyzer (TBA60M; 
Toshiba, Tokyo, Japan). LDL-cholesterol is 
calculated using the Friedewald formula P11 P as 
follows: 
LDL-C = total cholesterol – (HDL-C – 
(TG/2.2)) where all quantities are expressed 
in mmol/L 
H. pylori IgG was done using kits supplied 
by Neo Din Co., Ltd, Seoul, Korea. 
Radiological investigations include 
abdominal ultrasound using ultrasonic 
device power vision 6000, Toshiba by linear 
probe 8 MHZ. Ultrasound on the carotid 
arteries was done for all studied cases using 
B-mode ultrasound. B mode grey scale can 
be efficiently used in measuring the intima-




Statistical evaluation of all data was done on 
IBM-PC microprocessor computer using 
SPSS software for windows (Statistical 
Package for Social Sciences  version 11, 
USA) for data management and analysis 
and the excel for figures. Quantitative data 
were presented as mean ± SD. Quantitative 
variables with normal distribution were 
analyzed with a two-tailed, paired Student’s 
t test.  ANOVA (F) test with Bonferroni 
multiple comparisons were used for 
comparison between more than 2 groups. 
Qualitative variables such as comparison 
between proportion & percentage by Chi 
square with Yates correction as necessary. 
Pearson correlation coefficient was used to 
correlate between variables. P value under 




The age, sex and body mass index of cases 
were matched with the control (Table 1). H. 
pylori was higher in type 2 diabetic patients 
(38.3%) compared to the healthy control 
(20%), but this difference was statistically 
non significant (p value = 0.58l) (Table 1). H. 
pylori infection had no significant relation 
to the duration of diabetes (p. Value=0.602). 
The difference in H pylori seropositivity in 
relation to type of therapy was statistically 
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Table 1: H. pylori infection among controls and type 2 diabetic patients with their clinical 
characteristics (sex; body mass index and diabetic duration)   
Clinical Data H. pylori +ve H. pylori -ve P. value 
Patients (No; %) (60) 23/38.3% 37/61.7% 0.581 
Controls (No;  %) (15) 3/20% 12/80% NS 
Male (16) 4/25% 12/75% 0.44 
Female (44) 19/43% 25/57% NS 
BMI 37.16±5.2 31.6±5.1 0.140 (NS) 
Diab. duration (years) 7.9±5.2 7.3±4.8 0.602 (NS) 
Comparison between the different groups by using T test for numerical data and Chi square test for 
percentages. * P: mildly statistically significant (P<0.05). ** P: highly statistically significant (P<0.01). No: 
number. %: Percentage. NS: non-significant. BMI: Body mass index.  
 
Table 2: H. pylori infection among type 2 diabetic patients in relation to anti-diabetic therapy 
(oral; insulin and combined therapies) 
H. pylori Oral Insulin Combined Total P. value 
H. pylori +ve (No/%) 7/30.5% 3/13% 13/56.5% 23/100% 
0.335   H. pylori –ve (No/%) 10/27% 10/27% 17/45.9% 37/100% 
Total 17/28.3% 13/21.7% 30/50% 60/100% 
Comparison between the different groups by using Chi square test for percentages. No: number. %: 
Percentage. NS: non-significant.  
 
Table 3: H. pylori infection among type 2 diabetic patients in relation to some laboratory data 
(fasting blood glucose; hemoglobin A1C; Microalbuminuria and serum lipids profile) 
Laboratory Data H. pylori +ve H. pylori –ve P. value 
FBG (mg/dl) 331.2±101 289.4±99.6 0.120 
HbA1C% (gm %) 9.2±2.1 8.92±2.1 0.627 
Albuminuria (ug/ml) 108.7±121.7 138.8±122.8 0.357 
Cholesterol (mg/dl) 199.6±57.5 214.6±59.5 0.339 
Triglyceride (mg/dl) 180.7±64.1 137.6±48.4 <0.05 
HDL (mg/dl) 29.4±7.3 45.6±8.9 0.01 
LDL (mg/dl) 138.1±42.2 144.1±61.2 0.687 
Comparison between the different groups by using T test * P: mildly statistically significant (P<0.05). ** P: 
highly statistically significant (P<0.01). FBG: Fasting blood glucose. HAIC: hemoglobin A1c. HDL: High 
density lipoprotein. LDL: Low density lipoprotein.  
 
Table 4: Relation of H. pylori to the degree of retinopathy among type 2 diabetic patients 
Fundus Exam 
H. pylori +ve 
No: 23 





Normal Fundus (No/%) 15/65.2% 30/81.1% 45/75% 
0.118 
NS 
Non-Proliferative DR (No/%) 6/26% 4/11% 10/16.6% 
Proliferative DR (No/%) 2/8.8% 3/7.9% 5/8.4% 
Comparison between the different groups by using Chi square test for percentages. No: number. %: 
Percentage. NS: non-significant. DR: diabetic retinopathy.  
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Table 5: Relation of H. pylori seropositivity and inflammatory markers in type 2 diabetic 
patients 
Inflammatory Markers 
H. pylori +ve 
No: 23 
H. pylori –ve 
No: 37 
P. value 
WBCs  6.8±1.8 6.8±1.9 0.975 
ESR-1 27.6±17.2 24.8±20.1 0.581 
ESR-2 53.9±29.2 47.9±30.3 0.450 
CRP mg/l 14.8±7.8 9.2±7.1 0.01 
Fibrinogen mg/dl 432±176 283±98 0.001 
TNF-D pg/ml 67.3±8.1 47.3±9.1 0.01 
IL-6 pg/ml 48.2±19.2 52.3±32.1 0.581 
IL-1E pg/ml 19.3±4.1 17.2±3.1 <0.05 
Comparison between the different groups by using T test * P: mildly statistically significant (P<0.05). ** P: 
highly statistically significant (P<0.01). WBC: white blood cells. ESR: erythrocyte sedimentation rate. CRP: 
C- reactive protein. TNF-D: Tumor Necrosis Factor-alpha IL-6: Interleukin-6. IL-1E: Interleukin-1E.  
 
Table 6: Effect of H. pylori seropositivity on the carotid Intima Medial Thickness (IMT) of 
both Right and left common carotid arteries in type 2 diabetic patients 
Intima Medial Thickness 
H. pylori +ve 
No: 23 
H. pylori –ve 
No: 37 
P. value 
Right CCA in mm 7.78±1.41 8.16±1.69 0.373 
Left CCA in mm 8.08±1.54 8.21±1.62 0.760 
Comparison between the different groups by using T test * P: mildly statistically significant (P<0.05). ** P: 
highly statistically significant (P<0.01). CCA: common carotid artery.  
 
Table 7: H. pylori infection among type 2 diabetic patients with and without macrovascular 
complications (IHD or stroke).  
Type 2 DM 
H. pylori +ve 
No: 23 
H. pylori –ve 
No: 37 
P. value 
DM without MAVC (No/%) 13/30.9% 30/70.1% 0.373 
DM with MAVC (No/%) 10/58.8% 7/41.2% 0.760 
Total (No/%) 23/38.3% 37/61.7% 0.511 
Comparison between the different groups by using Chi square test for percentages. No: number. %: 
Percentage. MAVC: macrovascular complications.  
 
The patients with H. pylori seropositivity 
had significant high triglyceride and low 
HDL levels than those with negative H. 
pylori (180.7±64.1, 29.4±7.3 versus 137.6±48.4, 
45.6±8.9). The patients with H. pylori 
seropositivity had non-significant high FBG 
and HA1C levels as shown in Table 3. H. 
pylori seropositivity had no relation to the 
degree of diabetic retinopathy 
as demonstrated in Table 4. 
 
 H. pylori infection caused significant 
increase in the level of Fibrinogen, C 
reactive protein and some inflammatory 
cytokines as TNF-alpha and IL.1B as 
depicted in Table 5. Intima medial thickness 
of both right and left common carotid 
arteries were not significantly affected by H. 
pylori seropositivity (Table 6). No significant 
difference in prevalence of H. Pylori 
infection between diabetic patients with no 
evidence of macrovascular complications 
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(30.9%) and those with macrovascular 
















Figure 1: Inflammatory Markers in type 2 
diabetic patients with positive H Pylori versus 
those with negative H. Pylori. 
 
 
Figure 2: Macrovascular diabetic complications 
in type 2 diabetic patients with positive H. 




Recent and compelling evidence has shown 
the significant and independent role of 
inflammation, insulin resistance and 
subsequent endothelial dysfunction in the 
initiation and progression of 
atherothrombosis, superimposed on 
traditional risk factors12.  Infection by 
Helicobacter pylori has been 
epidemiologically linked to some 
extradigestive conditions, including 
ischemic heart diseases. Diabetic patients 
are at risk of cardiovascular and thrombo-
occlusive cerebral disease. There is a 
possible relationship between H. pylori 
infection and cardiovascular or 
cerebrovascular diseases in diabetic 
patients5. 
The present study found non significant 
increase in the prevalence of H. pylori 
infection among diabetic patients (38.3%) in 
relation to control healthy subjects (20%). 
No association between H. pylori infection 
among diabetic patients and duration of 
diabetes, BMI, sex of patients or their age. 
These findings support that found by 
Hamed et al13,  Anastasios et al14 who found 
no statistically significant increase in H. 
pylori seropositivity among diabetic patients 
and seems to be linked to the presence of 
atherosclerosis. Therefore, it seems that 
prevalence of H. pylori infection in diabetes 
mellitus reflects a balance between possible 
predisposing conditions (e.g.: gastroparesis 
diabeticorum) and preventing factors (e.g.: 
diabetes induced achlorhydria). It is certain 
that many other factors related to H. pylori 
colonization of gastric mucosa in diabetes 
mellitus remain unknown14. 
The present study found a non significant 
relation between H. pylori infection and 
glycaemic control in type 2 diabetic patients 
as evidenced by levels of fasting blood 
glucose (FBG), HbA1c and type of therapy 
(oral, insulin, combined).These findings 
support that found by Gillum 15 who found 
that H. pylori infection status was not 
significantly associated with glycated 
hemoglobin (HbA1c) in men aged 40-70 
years with or without history of diabetes. 
Also it supports Candelli and co-workers 16 
who found that H. pylori eradication in type 
1 diabetes doesn’t affect glycaemic control in 
such patients as evidenced by HbA1c level 
and daily insulin requirement. This 
difference may be attributed to differences 
in type of diabetes or age of patients 
between the present study and the study 
done by Begue et al17.            
The present study provides evidences that 
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 atherogenic modified lipid profile among 
patients with type 2 DM. H. pylori infection 
was associated with significant increase in 
triglyceride level,. Significant decrease in 
HDL level and non significant effect on 
levels of both LDL and total cholesterol. The 
present study supports Sung and his co-
workers (18) who found that H. pylori 
infection in healthy Korean adults was 
associated with atherogenic lipid 
profile(increase in total cholesterol, 
triglyceride, LDL cholesterol and decrease in 
HDL cholesterol) but this study had many 
limitations (subjects included were healthy, 
young, self selected and of relatively high 
socioeconomic status). While in the present 
study patients were type 2 diabetic aged 30-
60 years and of relatively lower 
socioeconomic status. A lot of studies which 
provided evidences for association between 
H. pylori infection and atherogenic modified 
lipid profile were done. A possible 
association of H. pylori infection and the 
development of coronary heart disease, 
thrombo-occlusive cerebral disease, or both, 
in diabetic patients. The importance of this 
link is highlighted by the possibility of an 
effective intervention against H. pylori 
infection 19. 
Eradication of H. pylori was found to be 
associated with significant decrease in CRP, 
significant increase in HDL and non 
significant effect on LDL, neither 
triglycerides nor total cholesterol among 
healthy people with H pylori infection2.   H. 
pylori infection is associated with 
cardiovascular risk factors, especially with 
triglyceride, HDL-cholesterol and 
apolipoproteins, independently from the 
presence of peptic ulcer 21. Association of H. 
pylori infection with modified atherogenic 
lipid profile may be due to 
lipopolysaccharides present in this gram 
negative bacteria which stimulate the 
production of many cytokines including 
tumor necrosis factor alpha(TNF- ǂ)which 
inhibit lipoprotein lipase activity leading to 
mobilization of lipids from the tissues and 
elevated serum triglycerides, lowered HDL 
cholesterol levels 22.   
The present study found significant increase 
in serum levels of TNF-ǂ and IL1-B in 
patients seropositive for H. pylori infection 
than seronegative ones. The presence of 
these inflammatory cytokines in the serum 
in association with H. pylori infection was 
demonstrated by a lot of studies. H. pylori 
seropositivity was found to cause increase in 
serum TNF-ǂ in human 23, 24 irrespective of 
the type pf strain included. Cag A positive 
H. pylori infection was found to be 
significantly associated with increased TNF-
ǂ level than Cag A negative one 25. Serum 
level of IL-1B was found to be significantly 
associated with H. pylori infection in human. 
A good experimental evidence of association 
between H pylori infection especially with 
toxigenic strains (Cag A and Vac A positive) 
with increased plasma levels of TNF-ǂ and 
IL-1B in rats was supplied by Brzozowski et 
al 26. Systemic increase in serum levels of 
TNF-ǂ and IL-1B in association with H 
pylori infection is due to 
lipopolysaccharides present in this gram 
negative bacteria.                                                                                     
In the present study significant increase in 
CRP level was found in association with H. 
pylori infection among type 2 diabetic 
patients. Oshima et al 27 found significant 
increase in CRP level in non smoker healthy 
subjects seropositive for H. pylori infection. 
Markus et al. (28) found significant 
association between CRP and H pylori 
seropositivity. CRP was also found to be 
increased in stroke patients seropositive to 
H. pylori infection than seronegative ones 
and this supports the hypothesis which 
considers H. pylori to be a cause of 
generalized inflammation, a recognized risk 
factor for atherosclerosis 8. 
The present study found significant increase 
in fibrinogen level in H. pylori positive 
diabetic patients in comparison to negative 
patients. The same results were found by 
Schumacher, et al 29 among patients with 
coronary heart disease. Zito et al 30 found an 
increase in level of plasma fibrinogen in H. 
pylori infected individuals even after 
controlling of possible confounding factors 
related to either infection or fibrinogen. The 
intima-medial thickness (IMT) of the carotid 
arteries is a marker of early atherosclerosis 
and the available epidemiological data 
indicate that increased IMT at or above 1mm
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 represents a risk for myocardial infarction 
and or cerebrovascular disease31. So, IMT 
was assessed in the present study (in both 
right and left common carotid arteries just 
1cm before bifurcation) and its relation to H. 
pylori was examined. The present study 
found a non significant difference in IMT of 
both CCAs in relation to H. pylori 
seropositivity among diabetic patients. 
Folsom et al32 found that H. pylori 
seropositivity was not associated with 
increased IMT of carotid artery measure of 
subclinical atherosclerosis among patients 
with CHD. Markus et al 28 found that H. 
pylori infection was not associated with 
increased IMT among normal individuals.  
Koksal et al33 found non significant 
difference in the IMT of carotid arteries 
between H. pylori positive and negative 
groups of patients who were identical in 
terms of sex distribution, smoking pattern, 
glucose, cholesterol, ESR, triglycerides, LDL, 
HDL, systolic and diastolic blood pressure 
levels. The lack of relation between H. pylori 
seropositivity and IMT of CCAs may be due 
to interference of multiple other risk factors 
in the process of atherosclerosis .These risk 
factors may be more related and affecting 
the progression of atherosclerosis than H. 
pylori seropositivity. However, virulence of 
H. pylori strain may be another possible 
factor that may lead to atherosclerosis (34) 
which in not included in our study. 
The present study found non significant 
relation between H. pylori seropositivity and 
microvascular complications (degree of 
retinopathy and nephropathy as indicated 
by level of microalbuminuria) or prevalence 
of macrovascular complications (IHD and 
cerebrovascular diseases). Tasi and Huang35 
found non significant association between 
H. pylori infection and angiographically 
documented coronary heart disease. 
Bielanski36 performed an epidemiological 
study in which no any clear correlation 
between H. pylori infection and IHD was 
found. Biagi, et al 37 found no positive 
association between seroprevalence of H. 
pylori infection and CHD. On the other 
hand, H. pylori infection might be one of the 
risk factors of atherosclerosis thorough 
inflammation (fibrinogen) and modulation 
of glucose and lipid profiles, which may be 
prevented by low antibiotics38.  Also, H. 
pylori seropositivity is a potential risk factor 
for increased brachial-ankle pulse wave 
velocity levels39. Majka et al40 demonstrated 
higher prevalence of H. pylori infection in 
patients with ischemic stroke. Also, some 
studies revealed no consistent associations 
of H. pylori infection with diabetes 
prevalence but it was associated with CHD 
prevalence41. The differences between 
previous studies and the present one may be 
due to predominant effect of cardiovascular 
risk factors in diabetic patients than direct 
effect of H. pylori infection. Another 
explanation is the role of toxigenic strains of 
H. pylori infection (Cag A and Vac A strains) 
which were proved to be highly related to 
IHD42 and atherosclerotic plaque 
instability43. These toxigenic strains were not 
examined in the present study. 
Epidemiologic study has suggested possible 
atherogenic roles for H. pylori. H. pylori 
infection is associated with arterial stiffness 
determined by pulse wave velocity in 
patients with type 2 diabetes mellitus44. The 
importance of this link is highlighted by the 
possibility of an effective intervention 
against H. pylori infection. 
It is concluded that, there is no significant 
increase in prevalence of H. pylori infection 
among type 2 diabetic patients. H. pylori 
infection is not related to age of the patients, 
their sex, BMI, duration of diabetes nor to 
the degree of glycaemic control. H. pylori 
infection has no direct relation to 
atherosclerosis (IMT) or vascular (micro and 
macrovascular) complications among type 2 
diabetic patients. However, H. pylori 
infection may increase atherosclerotic 
plaque formation, plaque instability and 
incidence of arterial thrombosis among  
these patients making them more prone to 
acute ischemic events .These effects are 
mediated through modification of lipid 
profile (increase in TG and decrease HDL 
levels), increase levels of inflammatory 
cytokines (TNF-alpha and IL-1B) and acute 
phase reactants (CRP and Fibrinogen).  
Due to the above mentioned results and 
conclusion of the present study, many 
relations need to be clarified in the future 
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studies. Effect of H. pylori on various 
clinical, chemical, radiological changes in 
diabetic patients presented with acute 
complications especially ischemic events 
needs clarification and studies. The relations 
especially the direct relation of H. pylori 
infection to atherosclerotic plaque formation 
and plaque instability in patients with DM 
can be studied in the future. Finally, larger 
number of patients, form of H. pylori 
infection (acute or chronic) and presence of 
virulent strains are important aspects which 




1. Gavin D, Ceriello A, paolisso G. 
Oxidative stress and diabetic vascular 
complications. Diabetes Care 1997; 19: 
257-267 
2. Murphy C. A possible risk factor for 
coronary artery disease. J. Am. Coll 
cardial. 1997, 6: 736-741 
3. Hennekens CH. Increasing burden of 
cardiovascular disease. Current 
knowledge and future directions for 
research on risk factors. Circulation 
1998; 97: 1095-102  
4. Koster D, De. Bruyne I, langlet P et al. 
Extra digestive manifestation of H. 
pylori infection. Endocr Res 2001; 27 (1– 
2): 171-177 
5. De Luis DA, Garcia Avello A, Lasuncion 
MA et al. Improvement in lipid and 
haemostasis patterns after Helicobacter 
pylori infection eradication in type 1 
diabetic patients. Clin Nutr. 1999; 18 (4): 
227 – 231  
6. Danesh J, Wong y, Ward M, and Muir J: 
Chronic infection and coronary heart 
disease. Heart 1999; 81 (3): 245 – 247  
7. Pietroiiusti A, Diomed M, Silvesterini M 
et al. Cytotoxin – associated gene. A- 
Positive Helicobacter pylori strains are 
associated with atherosclerotic stroke. 
Circulation 2002; 106(5): 580-4 
8. Sawayama Y, Ariyama I, Hamada M et 
al. Association between chronic 
Helicobacter pylori infection and acute 
ischemic stoke: Fukuoka Harasanshin 
Atherosclerosis Trial (FHAT). 
Atherosclerosis 2005; 178(2): 303-9 
9. The Expert Committee on the Diagnosis 
and Classification of DM. Report of the 
Expert Committee on the Diagnosis and 
Classification of DM. Diabetes Care 
2003; 10: 1183–1197 
10. Parving HH, Gall MA, Skott P. 
Prevalence and causes of albuminuria in 
NIDDM. Kidney Int 1990; 37: 243 
11. Friedewald W T, Levy R I, Fredrickson 
D S. Estimation of the concentration of 
low- density lipoprotein cholesterol in 
plasma, with out the use of the 
preparative ultracentrifuge. Clin. Chem 
1972; 18: 499-502 
12. Binodi-Zoccai GGL, Abbate A, Liuzzo G 
et al. Atherothrombosis. Inflammation 
and diabetes. J Am Coll Cardiol 2003; 
41: 1071 –107 7 
13. Hamed SA, Amine NF, Galal GM et al. 
Vascular risks and complications in 
diabetes mellitus: the role of 
helicobacter pylori infection. J Stroke 
Cerebrovasc Dis. 2008; 17(2): 86-94  
14. Anastasios R, Goritsas C, Papamihail C 
et al. Helicobacter pylori infection in 
diabetic patients: prevalence and 
endoscopic findings. Eur J Intern Med. 
2002; 13 (6): 376  
15. Gillum RF. Infection with Helicobacter 
pylori, coronary heart disease, 
cardiovascular risk factors, and systemic 
inflammation: the Third National 
Health and Nutrition Examination 
Survey. J Natl Med Assoc. 2004; 96 (11): 
1470-1476 
16. Candelli M, Rigante D, Marrietti G et al. 
Helicobacter pylori eradication rate and 
glycaemic control in young patients 
with type 1 diabetes. J Pediatr 
Gastroenterol Nutr 2004; (38) (4) 422-
425  
17. Begue RE, Gomez R, Compton T et al. 
Effect of Helicobacter pylori eradication 
in the glycaemia of children with type 1 
diabetes: a preliminary study. South 
Med J 2002; 95 (8): 842 – 845
El Hadidy M El Hadidy et al 
 
71
J T U Med Sc 2009; 4(1) 
18. Sung KC, Rhee EJ, Ryu SH et al. 
Prevalence of Helicobacter pylori 
infection and its association with 
cardiovascular risk factors in Korean 
adults. Int J Cardiol. 2005 Jul 20; 102(3): 
411-417.                        
19. De Luis DA, Lahera M, Canton R, et al: 
Association of Helicobacter pylori 
infection with cardiovascular and 
cerebrovascular disease in diabetic 
patients. Diabetes Care. 1998 Jul; 
21(7):1129-32. 
20. Kanbay M, Gur G, Yucel M, et al. Dose 
eradication of H pylori infection help to 
normalize serum lipid and CRP levels? 
Dig Dis Sci 2005 Jul; 50(7): 1228-1231 
21. Grunfeld C, Gulli R, Moser A.H et al. 
Effect of tumor necrosis factor 
administration in vivo on lipoprotein 
lipase activity in various tissues of rat. J 
Lipid Res.1989; 30: 579-585 
22. Sung KC, Rhee EJ, Ryu SH et al. 
Prevalence of Helicobacter pylori 
infection and its association with 
cardiovascular risk factors in Korean 
adults. Int J Cardiol 2005; 102(3):411-417 
23. Russo F, Jirillo E, Clemente C et al. 
Circulating cytokines and gastrin levels 
in a symptomatic subject infected by 
Helicobacter pylori. Immunopharmacol 
Immunotoxicol 2001; 23(1):13-24 
24. Kowalski M, Konturek P, Pieniazek P, et 
al: Prevalence of H pylori infection in 
coronary artery disease and effect of its 
eradication on coronary lumen 
reduction after percutaneous coronary 
angioplasty. Dig Dis Liver Dis 2001; 
33:229 
25. Szlachcic A, Sliwowski Z, Karczewska E 
et al. Helicobacter pylori and its 
eradication in rosacea. J Physiol 
Pharmacol 1999; 50(5): 777-786 
26. Brzozowski T, Konturek P, Konturek S 
et al. Water extract of Helicobacter 
pylori delay healing of chronic gastric 
ulcers in rats: role of cytokines and 
gastrin-somatostatin link. 
Digestion.1999; 60(1):22-33 
27. Oshima T, Ozone R, Yane Y, et al: 
Association of Helicobacter pylori 
infection with systemic inflammation 
and endothelial dysfunction in healthy 
male subjects. J. Am Coll Cardiol. 2005; 
45 (8): 1219-1222 
28. Markus HS, Risley P, Mendall MA et al. 
Helicobactrer pylori infection, the 
cytotoxin gene A strain, and carotid 
artery intima-media thickness. J 
cardiovascul Risk 2002 9(1): 1-6 
29. Schumacher A., Seljeflot I., Lerkerod A 
et al. Positive Chlamydia Pneumoniae 
serology is associated with elevated 
level of tumor necrosis factor alpha in 
patients with coronary heart disease. 
Atherosclerosis 2002; 164:153-160 
30. Zito F, Di Castelnuovo A, Orazio A et al. 
Helicobacter pylori infection and the 
risk of myocardial infarction: role of 
fibrinogen and its genetic control. 
Thromb Haemost 1999; 82: 14-18 
31. Simon A, Gariepy J, Chironi G et al. 
Intima-media thickness: a new tool for 
diagnosis and treatment of 
cardiovascular risk. J Hypertens 1999;  
20(2): 159-169 
32. Folsom A, Javier Nieto F, Sorlie P et al. 
Helicobacter pylori seropositivity and 
coronary heart disease incidence. 
Circulation 1998; 98:845-850 
33. Koksal A, Ekmekci Y, Karadeniz Y et al. 
Helicobacter pylori seropositivity and 
atherosclerosis risk factors. Dig Dis  
2004; 22(4): 386-389 
34. Mayr M, Kiechi S, Mendall MA et al. 
Increased Risk of atherosclerosis is 
confined to CagA- positive H. pylori 
strains: Prospective results from the 
Bruneck study. Stroke 2003; 34 (3): 610-
615 
35. Tasi CJ and Huang TY. Relation of 
Helicobacter pylori infection and 
angiographically documented coronary 
artery disease. Dig Dis Sci 2000; 45: 
1227-1232 
36. Bielanski W. Epidemiological study on 
Helicobacter pylori infection and 
extragastroduodenal disorders in Polish 
population. J Physiol Pharmacol 1999; 
50:.723-733 
37. Biagi B., Fabbrini D., Bocchini S et al. 
Seroprevalence of Helicobacter pylori 
infection in a group of hospitalized 
geriatric patients. Panminerva Med 
2000;  42:183-186
H. Pylori and vascular complications in type 2 diabetes mellitus 
 
72
J T U Med Sc 2009; 4(1) 
38. Longo-Mbenza B, Nkondi Nsenga J, 
Vangu Ngoma D et al. Prevention of the 
metabolic syndrome insulin resistance 
and the atherosclerotic diseases in 
Africans infected by Helicobacter pylori 
infection and treated by antibiotics. Int J 
Cardiol.2007 ; 121(3):229-238  
39. Yoshikawa H, Aida K, Mori A et al. 
Involvement of Helicobacter pylori 
infection and impaired glucose 
metabolism in the increase of brachial-
ankle pulse wave velocity. Helicobacter. 
2007; 12(5):559-566  
40. Majka J, Rog T, Konturek P et al. 
Influence of chronic H. pylori infection 
on ischemic cerebral stroke risk factors. 
Med Sci Monit 2002; 8: 675- 684 
41. Gillum RF. Infection with H. pylori, 
coronary heart disease, cardiovascular 
risk factors, and systemic inflammation: 
the Third National Health and Nutrition 
Examination Survey. J Natl Med Assoc 






























42. Singh R, Mc Mahon A, Patel H et al. 
Prospective analysis of the association of 
infection with Cag A bearing strains of 
H. pylori and coronary heart disease. 
Heart 2002; 88: 43-46 
43. Gabrielli M, Santoliquido A, Cremonini 
F et al. Cag A. positive cytotoxic H. 
pylori strains as a link between plaque 
instability and atherosclerotic stroke. 
Eur heart J 2004; 25: 64-68 
44. Ohnishi M, Fukui M, Ishikawa T et al 
Helicobacter pylori infection and 
arterial stiffness in patients with type 2 
diabetes mellitus. Metabolism. 2008; 
57(12): 1760-1764  
